International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbstract
Ver el documentoAcknowledgments
Ver el documentoInformation on authors
Ver el documentoExchange rates used in the report
Abrir esta carpeta y ver su contenidoChapter 1: Policies for praziquantel*
Abrir esta carpeta y ver su contenidoChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Abrir esta carpeta y ver su contenidoChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Abrir esta carpeta y ver su contenidoChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Abrir esta carpeta y ver su contenidoChapter 5: The international supply of praziquantel*
Abrir esta carpeta y ver su contenidoChapter 6: Demand for praziquantel and national distribution*
Cerrar esta carpetaChapter 7: Prices and production costs of praziquantel*
Ver el documentoThe price of praziquantel
Ver el documentoProduction costs and pricing strategies of major producers
Ver el documentoReferences
Ver el documentoOther documents in the DAP Research Series
Ver el documentoDAP Research Series No. 26
 

Chapter 7: Prices and production costs of praziquantel*

* By Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh.

This chapter examines the prices of praziquantel in various market segments, and the production costs of praziquantel. The section on pricing traces changes in praziquantel prices over time, and presents data on: current prices at which praziquantel is purchased by bulk suppliers; prices obtained by developing countries through tenders; and prices at which the drug is sold by producers in the private market in developed and developing countries. The section on production costs discusses the costs of manufacturing praziquantel faced by the major producers, and their pricing strategies. The section also explores problems experienced by Bayer and E. Merck in competing in the international market with lower-priced producers, who have successfully used process patent laws to develop alternative (and much cheaper) processes for producing praziquantel.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013